{"id":"W2095861620","doi":"10.1093/annonc/mdt182","title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":1274,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Roche","keywords":"Medicine; Epirubicin; Pertuzumab; Trastuzumab; Breast cancer; Internal medicine; Anthracycline; Docetaxel; Neoadjuvant therapy; Chemotherapy; Oncology; Tolerability; Ejection fraction; Carboplatin; Surgery; Adverse effect; Cancer; Heart failure; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01326154079515388,"score_gpt":0.3152371126023836,"score_spread":0.3019755718072297,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}